News

Gilead scheduling meet-up with Massachusetts AG over hep C pricing: Globe

Gilead Sciences is scheduling a meeting with Massachusetts Attorney General Maura Healey after last week's threat of legal action against the company. And though some legal experts doubt Healey's standing in a court fight over Gilead's high prices on hep C drugs, the AG's office apparently sees some backing for the idea.

Don't blame industry trends for Sandoz's slide, analyst says. But biosimilars? Maybe

Last week, Novartis' Sandoz unveiled weak numbers, blaming them on broader generics-industry trends. But at least one analyst isn't convinced that's the culprit.

Novartis braces for multibillion-dollar generics hit as Gleevec copies launch

It's a dark day at Novartis. Sun Pharma rolled out its copycat version of Novartis' blockbuster cancer drug Gleevec, setting the Swiss drugmaker up for a big hit to 2016 sales.

Was Allergan's CEO simply touting a Texas plant expansion--or nudging watchdogs on Pfizer merger, too?

Allergan's $160 billion inversion merger with Pfizer and its attendant whacking of U.S. taxes has raised some hackles in Washington. Now, Allergan seems to be offering a bit of sugar to make the tax-avoiding medicine go down by talking about doubling employment at its flagship plant in Texas.

Roche sees no 'short term' pricing pressure for company's cancer drugs: Reuters

Don't expect Roche's cancer drugs to get caught in the crosshairs as payers ratchet up the pressure on drug prices, the company's head of pharmaceuticals, Daniel O'Day, told Reuters.

Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: Undercut them. Big-time.

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced to the point where surgery is not an option.

Angered by Walgreens deal, Express Scripts blocks access to Valeant's Glumetza

PBM giant Express Scripts has long been a leader in the fight to tamp down drug prices, and now, it's using its formulary power to freeze out a diabetes drug from controversial Valeant.

UPDATED: Amgen beats in Q4 as established drugs come through

Amgen had a steady stream of significant new drug approvals in 2015, like the FDA nod for its Repatha which is in a new class of cholesterol fighters that are expected to generate significant sales. But Repatha and several others are too early in their launch to register separately on the sales line, and it was growth in sales of Amgen's tried-and-true drugs that allowed the biotech to breeze by analyst expectations.

Strong Q4 showings for AbbVie abroad offset Humira, Viekira stumbles at home

Over the past couple of quarters, AbbVie investors have bristled at the sight of top-seller Humira missing expectations outside the U.S. In Q4, though, the world's best seller rebounded outside its home country, topping predictions to help sales and profits stay generally in line despite a rough U.S. quarter for hep C drug Viekira Pak.

Gilead Sciences' John Martin stepping out of CEO role after two decades, is replaced by John Milligan

John Martin, who has led Gilead Sciences through two decades of incredible growth and more recently significant controversy over the pricing it is hep C cures, is stepping up and out of the CEO role. President John Milligan has been named CEO as Martin moves up to the executive chairman of the board.

Celgene boosts Q4 sales by 24% on stalwart Revlimid, up-and-coming Otezla

Celgene's fourth-quarter sales grew by 24% to $2.5 billion, taking full-year revenue up to $9.25 billion, a 21% hike; it's expecting another sales leap for 2016--albeit slightly smaller--with a forecast of $10.5 billion to $11 billion. Its new drug Otezla chipped in $183 million for the quarter. 

Bristol-Myers immunotherapies soar, but Eliquis haul tops the charts

Bristol-Myers Squibb has been riding high thanks to its lead in the ultrahot immuno-oncology space. But in Q4, it wasn't just its cancer stars that pitched in to help revenue beat expectations.

Riding Q4 diabetes growth, Lilly aims for even more with Jardiance

It was a "very quiet quarter overall" for Eli Lilly & Co., in the words of Bernstein analyst Tim Anderson. But the company expects things to get plenty more exciting if its diabetes med Jardiance wins a label change, an event it's anticipating for the second half of this year.

UPDATED: State AG's protest against Gilead pricing destined to fail, legal observers suggest

The Massachusetts attorney general can complain all she wants about Gilead Sciences' hepatitis C pricing. But that doesn't mean a legal action against the company has a chance of getting anywhere.

UPDATED: Big investor pushes 'underperforming' J&J to step up or split up

Should Johnson & Johnson join the Big Pharma split-up club? One of its major shareholders thinks so, and it's pressing activist investors to join the cause.

Roche looks ahead to immuno-oncology, MS to back up big-selling cancer meds

Roche counts on its tried-and-true cancer drugs Rituxan, Avastin and Herceptin to bring home the bacon, and the meds did not disappoint in 2015. But despite the drugs' strong performance, Roche still missed on profits last year, disheartening news for the company as it readies itself for biosimilar competition to some of its top sellers.

Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance

Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance.

Novartis CEO Jimenez sees U.S. pricing power draining away

Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does--and he says they're not coming back.

Revved-up Tecfidera sales power Biogen in Q4

Biogen CEO George Scangos and his team tamped down investor expectations earlier this month at the J.P. Morgan Healthcare Conference, saying that the company faced headwinds. But the drugmaker got those winds into its sails, and sales, this quarter, racing past Wall Street expectations as MS med Tecfidera regained the momentum lost earlier last year.